Download the presentation here: PDF

But Also Significant Hurdles
• Technology not enough, must prove lower abuse – but how?
• FDA labeling may provide false sense of security, resulting in
increased/less scrutinized use.
• Purdue’s patent estate.
51
TheraQuest has an abuse-deterrent extended release Tramadol in Phase I.
© Defined Health, 2009
Pain Insight Briefing